Atrial natriuretic peptide prevents the mitochondrial permeability transition pore opening by inactivating glycogen synthase kinase 3β via PKG and PI3K in cardiac H9c2 cells

European Journal of Pharmacology

Volumn 695, Issue 1-3, 2012, Pages 13-19

  Hong, Lan ^a   Xi, Jinkun ^b   Zhang, Yidong ^b   Tian, Wei ^b   Xu, Jingman ^b   Cui, Xun ^a   Xu, Zhelong ^c  

^a YANBIAN UNIVERSITY   (China)

^b HEBEI UNITED UNIVERSITY   (China)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

ANP; GSK 3 ; mPTP; PI3K; PKG; Reperfusion injury

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ATRIAL NATRIURETIC FACTOR; CYCLIC GMP DEPENDENT PROTEIN KINASE; CYCLOSPORIN A; GLYCOGEN SYNTHASE KINASE 3BETA; KT 5823; PHOSPHATIDYLINOSITOL 3 KINASE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; GENETIC TRANSFECTION; HEART MUSCLE CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL PERMEABILITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; REPERFUSION INJURY; SIGNAL TRANSDUCTION;

ANIMALS; ATRIAL NATRIURETIC FACTOR; CELL LINE; CYCLIC GMP-DEPENDENT PROTEIN KINASES; ENZYME ACTIVATION; GLYCOGEN SYNTHASE KINASE 3; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; MYOCARDIUM; OXIDATIVE STRESS; PHOSPHATIDYLINOSITOL 3-KINASES; RATS; SIGNAL TRANSDUCTION;

EID: 84867571658     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2012.07.053     Document Type: Article

References (37)

1. L. Argaud, O. Gateau-Roesch, D. Muntean, L. Chalabreysse, J. Loufouat, D. Robert, and M. Ovize Specific inhibition of the mitochondrial permeability transition prevents lethal reperfusion injury J. Moll. Cell Cardiol. 38 2005 367 374
2. G. Bhamra, D. Hausenloy, S. Davidson, R. Carr, M. Paiva, A. Wynne, M. Mocanu, and D. Yellon Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening Basic Res. Cardiol. 103 2008 274 284
3. G. Chanoit, S. Lee, J. Xi, M. Zhu, R.A. McIntosh, R.A. Mueller, E.A. Norfleet, and Z. Xu Exogenous zinc protects cardiac cells from reperfusion injury by targeting mitochondrial permeability transition pore through inactivation of glycogen synthase kinase-3β Am. J. Physiol. 295 2008 H1227 1233
4. G. Chanoit, J. Zhou, S. Lee, R. McIntosh, X. Shen, D. Zvara, and Z. Xu Inhibition of phosphodiesterases leads to prevention of the mitochondrial permeability transition pore opening and reperfusion injury in cardiac H9c2 cells Cardiovasc. Drugs Ther. 25 2011 299 306
5. P. Cohen, and S. Frame The renaissance of GSK3 Nat. Rev. Mol. Cell Biol. 2 2001 769 776
6. A.D.T. Costa, S.V. Pierre, M.V. Cohen, J.M. Downey, and K.D. Garlid cGMP signalling in pre- and post-conditioning: the role of mitochondria Cardiovasc. Res. 77 2007 344 352
7. M. Crompton The mitochondrial permeability transition pore and its role in cell death Biochem. J. 341 1999 233 249
8. A. Das, L. Xi, and R.C. Kukreja Protein kinase G-dependent cardioprotective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3β J. Biol. Chem. 283 2008 29572 29585
9. S.M. Davidson, D. Hausenloy, M.R. Duchen, and D.M. Yellon Signalling via the reperfusion injury signalling kinase (RISK) pathway links closure of the mitochondrial permeability transition pore to cardioprotection Int. J. Biochem. Cell Biol. 38 2006 414 419
10. L. Gomez, M. Paillard, H. Thibault, G. Derumeaux, and M. Ovize Inhibition of GSK3β by postconditioning Is required to prevent opening of the mitochondrial permeability transition pore during reperfusion Circulation 117 2008 2761 2768
11. E.J. Griffiths, and A.P. Halestrap Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion Biochem. J. 307 1995 93 98
12. D. Hausenloy, and D. Yellon Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection Heart Fail. Rev. 12 2007 217 234
13. D.J. Hausenloy, M.R. Duchen, and D.M. Yellon Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury Cardiovasc. Res. 60 2003 617 625
14. A. Hempel, M. Friedrich, K.D. Schluter, W.G. Forssmann, M. Kuhn, and H.M. Piper ANP protects against reoxygenation-induced hypercontracture in adult cardiomyocytes Am. J. Physiol. 273 1997 H244 H249
15. Y. Jang, H. Wang, J. Xi, R.A. Mueller, E.A. Norfleet, and Z. Xu NO mobilizes intracellular Zn2 via cGMP/PKG signaling pathway and prevents mitochondrial oxidant damage in cardiomyocytes Cardiovasc. Res. 75 2007 426 433
16. R.S. Jope, and G.V.W. Johnson The glamour and gloom of glycogen synthase kinase-3 Trends Biochem. Sci. 29 2004 95 102
17. M. Juhaszova, D.B. Zorov, S.H. Kim, S. Pepe, Q. Fu, K.W. Fishbein, B.D. Ziman, S. Wang, K. Ytrehus, C.L. Antos, E.N. Olson, and S.J. Sollott Glycogen synthase kinase-3β mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore J. Clin. Invest. 113 2004 1535 1549
18. M. Juhaszova, D.B. Zorov, Y. Yaniv, H.B. Nuss, S. Wang, and S.J. Sollott Role of glycogen synthase kinase-3{beta} in cardioprotection Circ. Res. 104 2009 1240 1252
19. S. Kasama, M. Furuya, T. Toyama, S. Ichikawa, and M. Kurabayashi Effect of atrial natriuretic peptide on left ventricular remodelling in patients with acute myocardial infarction Eur. Heart J. 29 2008 1485 1494
20. T. Kato, J. Muraski, Y. Chen, Y. Tsujita, J. Wall, C.C. Glembotski, E. Schaefer, M. Beckerle, and M.A. Sussman Atrial natriuretic peptide promotes cardiomyocyte survival by cGMP-dependent nuclear accumulation of zyxin and Akt J. Clin. Invest. 115 2005 2716 2730
21. M. Kitakaze, M. Asakura, J. Kim, Y. Shintani, H. Asanuma, T. Hamasaki, O. Seguchi, M. Myoishi, T. Minamino, T. Ohara, Y. Nagai, S. Nanto, K. Watanabe, S. Fukuzawa, A. Hirayama, N. Nakamura, K. Kimura, K. Fujii, M. Ishihara, Y. Saito, H. Tomoike, and S. Kitamura Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials Lancet 370 2007 1483 1493
22. H. Kook, H. Itoh, B.S. Choi, N. Sawada, K. Doi, T.J. Hwang, K.K. Kim, H. Arai, Y.H. Baik, and K. Nakao Physiological concentration of atrial natriuretic peptide induces endothelial regeneration in vitro Am. J. Physiol. 284 2003 H1388 H1397
23. M. Kuhn Molecular physiology of natriuretic peptide signalling Basic Res. Cardiol. 99 2004 76 82
24. T. Miki, T. Miura, H. Hotta, M. Tanno, T. Yano, T. Sato, Y. Terashima, A. Takada, S. Ishikawa, and K. Shimamoto Endoplasmic reticulum stress in diabetic hearts abolishes erythropoietin-induced myocardial protection by impairment of phospho-glycogen synthase kinase-3β mediated suppression of mitochondrial permeability transition Diabetes 58 2009 2863 2872
25. M. Nishihara, T. Miura, T. Miki, M. Tanno, T. Yano, K. Naitoh, K. Ohori, H. Hotta, Y. Terashima, and K. Shimamoto Modulation of the mitochondrial permeability transition pore complex in GSK-3β-mediated myocardial protection J. Mol. Cell Cardiol. 43 2007 564 570
26. S.-S. Park, H. Zhao, Y. Jang, R.A. Mueller, and Z. Xu N6-(3-Iodobenzyl)-adenosine-5'-N-methylcarboxamide confers cardioprotection at reperfusion by inhibiting mitochondrial permeability transition pore opening via glycogen synthase kinase 3β J. Pharmacol. Exp. Ther. 318 2006 124 131
27. S.S. Park, H. Zhao, R. Mueller, and Z. Xu Bradykinin prevents reperfusion injury by targeting mitochondrial permeability transition pore through glycogen synthase kinase 3β J. Mol. Cell Cardiol. 40 2006 708 716
28. S.S. Park, H. Zhao, R.A. Mueller, and Z.L. Xu Bradykinin prevents reperfusion injury by targeting mitochondrial permeability transition pore through glycogen synthase kinase 3 beta J. Mol. Cell Cardiol. 40 2006 708 716
29. M.A. Rastegar, Á. Végh, J.G. Papp, and J.R. Parratt Atrial natriuretic peptide reduces the severe consequences of coronary artery occlusion in anaesthetized dogs Cardiovasc. Drugs Ther. 14 2000 471 479
30. K. Sangawa, K. Nakanishi, K. Ishino, M. Inoue, M. Kawada, and S. Sano Atrial natriuretic peptide protects against ischemia-reperfusion injury in the isolated rat heart Ann. Thorac. Surg. 77 2004 233 237
31. S. Shanmuganathan, D.J. Hausenloy, M.R. Duchen, and D.M. Yellon Mitochondrial permeability transition pore as a target for cardioprotection in the human heart Am. J. Physiol. 289 2005 H237 242
32. M.-S. Suleiman, A.P. Halestrap, and E.J. Griffiths Mitochondria: a target for myocardial protection Pharmacol. Ther. 89 2001 29 46
33. Y. Takata, Y. Hirayama, S. Kiyomi, T. Ogawa, K. Iga, T. Ishii, Y. Nagai, and C. Ibukiyama The beneficial effects of atrial natriuretic peptide on arrhythmias and myocardial high-energy phosphates after reperfusion Cardiovasc. Res. 32 1996 286 293
34. J.N. Weiss, P. Korge, H.M. Honda, and P. Ping Role of the mitochondrial permeability transition in myocardial disease Circ. Res. 93 2003 292 301
35. J. Xi, W. Tian, L. Zhang, Y. Jin, and Z. Xu Morphine prevents the mitochondrial permeability transition pore opening through NO/cGMP/PKG/Zn2/GSK- 3{beta} signal pathway in cardiomyocytes Am. J. Physiol. 298 2010 H601 607
36. X.-M. Yang, S. Philipp, J. Downey, and M. Cohen Atrial natriuretic peptide administered just prior to reperfusion limits infarction in rabbit hearts Basic Res. Cardiol. 101 2006 311 318
37. W. Zhou, C. Dasgupta, S. Negash, and J.U. Raj Modulation of pulmonary vascular smooth muscle cell phenotype in hypoxia: role of cGMP-dependent protein kinase Am. J. Physiol. 292 2007 L1459 1466